Biofrontera AG, a biopharmaceutical company, primarily focuses on the discovery, development, and distribution of dermatological drugs and dermatologically tested cosmetics for the treatment and care of diseased skin. Biofrontera AG was founded in 1997 and is based in Leverkusen, Germany.
Leverkusen, Germany, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the full year 2020. Biofrontera Group's preliminary unaudited revenue for the period January 1 to December 31, 2020 was in the range of EUR 30.3 million to EUR 30.6 million compared to EUR 31.3 million in 2019.Preliminary revenues from product sales in the US were around EUR 16.6 million, compared to EUR 23.3 million in 2019 (-29%). In Germany, revenues from product sales amounted to approximately EUR 5.2 million, compared to EUR 4.6 million in fiscal year 2019 (+13%). In the rest of Europe, the Company generated product sales of around EUR 2.1 million, compared ...
The global Actinic Keratosis Drugs market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regional analysis. The report helps readers to clearly understand the current and
The proposed Dermatology Treatment Devices Market report will encompass all the qualitative & quantitative aspects including the market size, market estimates, growth rates & forecasts & hence will give you a holistic view of the market. The study also includes
NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Biofrontera AG (NASDAQ:BFRA) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 12, 2020 at 2:00 PM Eastern Time.